Quarterly Result19 May 2026, 11:51 am
Kwality Pharma FY26 Revenue Up ~36% YoY to ₹503 Cr
AI Summary
Kwality Pharmaceuticals Ltd (KPL) reported its audited financial results for the year ended March 31, 2026. The company achieved its highest-ever quarterly and annual revenues, with FY26 consolidated revenues reaching ₹503 crore, a ~36% increase YoY. EBITDA margins improved to 24%, and Profit After Tax (PAT) grew by approximately 69% YoY to ₹67.34 crore. KPL's credit rating was upgraded to BBB+ by ICRA. The company also focused on expanding its international presence and investing in its biologics pipeline.
Key Highlights
- KPL's FY26 consolidated revenue reached ₹503 crore, up ~36% YoY.
- EBITDA margins improved to 24%, a 200 bps expansion compared to FY25.
- FY26 Profit After Tax (PAT) grew ~69% YoY to ₹67.34 crore.
- ICRA upgraded KPL's credit rating to BBB+ from B+.
- Company is investing in biologics pipeline with monoclonal antibodies development.
Price Impact
More from KPL